[Treatment strategies of acute and chronic hepatitis C].
There is a overview of actual regimens proposed for treatment of acute and chronic hepatitis C. The new formulations of interferon alpha obtained by pegylation--PEG-IFN-s have resulted in improved efficacy as monotherapy and in combination with ribavirin. The results of clinical trials and therapeutical recommendations have been presented.
Gładysz
Andrzej
A
Katedra i Klinika Chorób Zakaźnych, Akademii Medycznej we Wrocławiu.
Inglot
Małgorzata
M
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a